Hematuria Treatment Market is expected to reach US$ 1,103.61 million by 2028

According to our latest study on “Hematuria Treatment Market Forecast to 2028 – COVID-19 Impact and Global Analysis – by Treatment, Indication, Type, and End User,” the market is projected to reach US$ 1,103.61 million by 2028 from US$ 932.89 million in 2021; it is expected to grow at a CAGR of 2.4% from 2021 to 2028. The report highlights the key factors driving the market growth and prominent players with their developments in the market.

Based on treatment, the hematuria treatment market is segmented into drugs, therapies, and others. The drugs segment held the largest share of the market in 2020. The increasing awareness about treatment options and improving healthcare expenditure are among the major factors boosting the market growth of the segment. Further, the market for the drugs segment is expected to grow at the highest CAGR during 2021–2028.

The growth of the hematuria treatment market is primarily attributed to the factors such as the high prevalence of hematuria-associated indications, and rise in preference for advanced therapies. However, the undiagnosed cases of associated indications affect the hematuria treatments, thereby hindering the market growth. AstraZeneca; Bristol-Myers Squibb Company; F. HOFFMANN-LA ROCHE LTD.; GlaxoSmithKline plc.; Janssen Pharmaceuticals; Merck & Co., Inc.; Novartis AG; Pfizer Inc.; Sun Pharmaceutical Industries Ltd; and Boehringer Ingelheim International GmbH are among the leading companies operating in the market.

Hematuria Treatment Market, by Region, 2020 (%)

---

Hematuria Treatment Market Size & Share Industry Growth 2028

Download Free Sample

---

Hematuria Treatment Market Forecast to 2028 - COVID-19 Impact and Global Analysis By Treatment (Drugs, Therapies, and Others), Indication (Urinary Tract Infections, Kidney Stones, Urethritis, Blood Cancer, Bladder Stones, Prostate Cancer, Cystitis, Trauma, Vigorous Exercise, Polycystic Kidney Disease, Endometriosis, and Menstruation), Type (Macroscopic Hematuria, Microscopic Hematuria, Idiopathic Hematuria, and Jogger’s Hematuria), and End User (Hospitals, Clinics, and ASC’s, and Others) and Geography

The report segments Hematuria Treatment market as Follows:

By Treatment

• Drugs
• Therapies
• Others

By Indication

• Urinary Tract Infections
• Kidney Stones
• Urethritis
• Blood Cancer
• Bladder Stones
• Prostate Cancer
• Cystitis, Trauma
• Vigorous Exercise
• Polycystic Kidney Disease
• Endometriosis
• Menstruation

By Type

• Macroscopic Hematuria
• Microscopic Hematuria
• Idiopathic Hematuria
• Jogger’s Hematuria

By End User

• Hospitals
• Clinics
• ASC’s
• Others

By Geography

• North America
  • US
  • Canada
  • Mexico
• Europe
  • France
  • Germany
  • UK
  • Spain
  • Italy
  • Rest of Europe
• Asia Pacific (APAC)
  • China
  • India
  • Japan
  • Australia
  • South Korea
  • Rest of APAC
• Middle East and Africa (MEA)
  • Saudi Arabia
  • UAE
  • South Africa
  • Rest of MEA
• South and Central America (SCAM)
  • Brazil
  • Argentina
  • Rest of SCAM